Medtronic sees profit slip despite uptick in revenue

Medtronic ($MDT) pulled in $4.1 billion in revenue last quarter, but charges, litigation costs and expenses dragged profits down by about 25%.

The devicemaker posted $646 million in net profit in the fiscal second quarter, down from $864 million in the same period last year. Quarterly revenue ticked up 2%, sped along by growth in the company's cardiac and vascular and restorative therapies businesses.

Notably, Medtronic grossed $429 million from its coronary devices, a 14% jump, and $344 million from surgical technologies, good for a 15% boost over last year. However, that growth comes amid continued declines for some of the company's largest segments, including defibrillators, which fell 3%, and spinal devices, which notched a 7% revenue decline.

Medtronic CEO Omar Ishrak rarely misses a chance to affirm the company's commitment to growing its emerging markets presence, and the devicemaker did just that in Q2, picking up $464 million from the likes of China and India, a 14% increase over the same period last year.

"Our growth was broad-based across several businesses and geographies, driven by continued stabilization of our end markets and the ongoing successful execution of new product launches," Ishrak said in a statement.

Among those launches and globe-spanning growth spurts, Medtronic is inching toward European approval for its Engager heart valve, looking to unseat Edwards Lifesciences ($EW) in that market, and the company has made a series of big bets in China, closing an $816 million deal for a devicemaker there.

- read Medtronic's release
- check out the full results (PDF)

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,